24 results
6-K
EX-99.1
SPRC
SciSparc Ltd
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
Research, the global opioid market was valued at $22.8 billion in 2022 and is anticipated to grow at a compound annual growth rate of 1.4% from 2023 … to 2030. The increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
.
implementation of the federal physician payment transparency requirements, or the Sunshine Act. The Substance Use-Disorder Prevention that Promotes Opioid … . It is a major symptom in many medical conditions and can interfere with a person’s quality of life and general functioning. Opioid medications can provide
6-K
EX-99.1
SPRC
SciSparc Ltd
31 Oct 23
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
8:15am
to a report by Grand View Research entitled “Opioid Market Size, Share & Trends Analysis Report By Product (IR/ Short Acting Opioids, ER/Long-Acting Opioids … ”, the global opioid market size was valued at $22.8 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 1.4% from 2023
6-K
EX-99.1
yobva3z
1 Jun 22
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
4:11pm
6-K
EX-99.1
b6tvtyvj5773d cso
2 Dec 20
Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain
9:25am
424B4
mfh7jzbvb7bu225
2 Apr 20
Prospectus supplement with pricing info
5:28pm
F-1/A
69lz0dov
31 Mar 20
Registration statement (foreign) (amended)
11:31am
F-1/A
are x3313lkrecux
30 Mar 20
Registration statement (foreign) (amended)
12:29pm
F-1/A
27dhde hg2d
26 Mar 20
Registration statement (foreign) (amended)
12:00am
F-1/A
ic0 os7f2xqmok1
19 Mar 20
Registration statement (foreign) (amended)
12:21pm
424B5
9tohlb fugp
5 Dec 19
Prospectus supplement for primary offering
5:29pm
424B5
v7mki4p2vue6o3
1 Apr 19
Prospectus supplement for primary offering
6:57am
6-K
EX-99.1
haf8a6yegfiz1utjg3s
6 Dec 18
Therapix Biosciences Reports Third
6:18am
424B2
v4kf 8yodilazp18
9 Aug 18
Prospectus for primary offering
11:19am